Liver fibrosis is considered as a progressive pathological process involving multiple cellular and molecular events that lead to deposition of excess matrix proteins in the extracellular space. When that process is combined with ineffective regeneration and repair, there is increasing distortion of the normal liver architecture, and the end result is cirrhosis. Emerging anti-fibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins. Although many therapeutic interventions are effective in experimental models of liver fibrosis, the mechanisms underlying the anti-fibrotic effect on liver fibrosis remain unclear. The aim of the present study was to investigate the underlying mechanisms of anti-fibrotic effect of angiotensin converting enzyme inhibitor (ACEI) on experimental liver fibrosis induced by carbon tetrachloride (CCl4). Thirty five white albino male rats of 150-200g average weight were randomly divided into three groups, Group I: The control group (n = 10), Group II: CCl4 injected rats without any treatment (n = 10) and Group III: CCl4 injected rats that received an ACEI, perinodopril , dissolved in distilled water, 6mg/kg/day for 4 weeks (n = 15). Venous blood was collected from retro orbital vein for serum separation for assessment of liver functions. Liver tissue was subdivided into three portions for: pathological examination, estimation of transforming growth factor-β1 (TGF-β1) and matrix metalloproteinase-9 (MMP-9) by ELISA and expression of nuclear factor- kappa beta (NF-κB) in a trial to understand the mechanism underlying the anti-fibrotic effect of ACEI. Tissue TGF-β1, MMP-9 and NF-κB were significantly higher in CCl4 group (group II) compared with control group (group I) and they were decreased significantly with administration of ACEI with CCl4 (group III). In conclusion, ACEI attenuates the progression of hepatic fibrosis induced by CCl4 by reducing expression of NF-κB, TGF-β1, and MMP- 9.
Shawky, H., Marzouk, S., Obaia, E., & Hassouna, A. (2007). Perinodopril, an angiotensin converting enzyme inhibitor, attenuates experimental hepatic fibrosis. Bulletin of Egyptian Society for Physiological Sciences, 27(1), 381-392. doi: 10.21608/besps.2007.37175
MLA
Heba Shawky; Samar Marzouk; Eman Obaia; Amira Hassouna. "Perinodopril, an angiotensin converting enzyme inhibitor, attenuates experimental hepatic fibrosis". Bulletin of Egyptian Society for Physiological Sciences, 27, 1, 2007, 381-392. doi: 10.21608/besps.2007.37175
HARVARD
Shawky, H., Marzouk, S., Obaia, E., Hassouna, A. (2007). 'Perinodopril, an angiotensin converting enzyme inhibitor, attenuates experimental hepatic fibrosis', Bulletin of Egyptian Society for Physiological Sciences, 27(1), pp. 381-392. doi: 10.21608/besps.2007.37175
VANCOUVER
Shawky, H., Marzouk, S., Obaia, E., Hassouna, A. Perinodopril, an angiotensin converting enzyme inhibitor, attenuates experimental hepatic fibrosis. Bulletin of Egyptian Society for Physiological Sciences, 2007; 27(1): 381-392. doi: 10.21608/besps.2007.37175
)
View on SCiNiTO